The interplay of knowledge, motivation, and treatment response in medication adherence among patients with chronic myeloid leukemia treated with Imatinib

被引:0
作者
Omran, Mervat M. [1 ]
Ibrahim, Amel B. [2 ]
Abdelfattah, Raafat [3 ]
Moussa, Heba S. [4 ]
Shouman, Samia A. [1 ]
Hamza, Marwa S. [5 ]
机构
[1] Cairo Univ, NCI, Canc Biol Dept, Pharmacol Unit, Kasr Al Eini St, Cairo 11796, Egypt
[2] Zawia Univ, Fac Med, Dept Pharmacol, Az Zawiyah, Libya
[3] Cairo Univ, NCI, Med Oncol Dept, Cairo, Egypt
[4] Cairo Univ, NCI, Clin Pathol Dept, Cairo, Egypt
[5] British Univ Egypt, Fac Pharm, Clin Pharm Practice Dept, El Sherouk City, Cairo, Egypt
关键词
Imatinib mesylate; CML; adherence; trough; peak; CHRONIC MYELOGENOUS LEUKEMIA; CYTOGENETIC RESPONSES; TYROSINE KINASE; BLAST CRISIS; THERAPY; NONADHERENCE; OUTCOMES;
D O I
10.1080/10428194.2024.2403671
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic Myeloid Leukemia (CML) requires consistent medication adherence to Imatinib (IM) for optimal outcomes, however, adherence to oral chemotherapy is challenging. This observational study explores the relationship between patient knowledge, motivation, and adherence to IM therapy, and their collective impact on clinical outcomes. A prospective, observational study was conducted with 101 CML patients. The 6-Item Morisky Medication Adherence Scale (MMAS-6) was used to assess adherence, motivation, and knowledge levels. The study found that high motivation was significantly associated with lower BCR-ABL expression (p = 0.025). Patients with high knowledge and motivation had a 71% favorable response rate, compared to 0% in those with low knowledge and motivation (p = 0.01). As conclusion both patient motivation and knowledge are crucial for favorable treatment outcomes in CML. High levels of both significantly correlate with better clinical responses. Tailored interventions to enhance patient knowledge and motivation are essential.
引用
收藏
页码:123 / 130
页数:8
相关论文
共 50 条
[31]   Different immunoprofiles in patients with chronic myeloid leukemia treated with imatinib, nilotinib or dasatinib [J].
Hayashi, Yoshiki ;
Nakamae, Hirohisa ;
Katayama, Takako ;
Nakane, Takahiko ;
Koh, Hideo ;
Nakamae, Mika ;
Hirose, Asao ;
Hagihara, Kiyoyuki ;
Terada, Yoshiki ;
Nakao, Yoshitaka ;
Hino, Masayuki .
LEUKEMIA & LYMPHOMA, 2012, 53 (06) :1084-1089
[32]   Treatment selection after imatinib resistance in chronic myeloid leukemia [J].
Jabbour, Elias ;
Cortes, Jorge ;
Kantarjian, Hagop .
TARGETED ONCOLOGY, 2009, 4 (01) :3-10
[33]   Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib [J].
Stein, Brady ;
Smith, B. Douglas .
CLINICAL THERAPEUTICS, 2010, 32 (05) :804-820
[34]   Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients [J].
Moon, Joon Ho ;
Sohn, Sang Kyun ;
Kim, Shi Nae ;
Park, Seon Yang ;
Yoon, Sung Soo ;
Kim, In Ho ;
Kim, Hyeoung Joon ;
Kim, Yeo Kyeoung ;
Min, Yoo Hong ;
Cheong, June Won ;
Kim, Jin Seok ;
Jung, Chul Won ;
Kim, Dong Hwan .
MEDICAL ONCOLOGY, 2012, 29 (02) :1179-1185
[35]   Outcome of Chronic Myeloid Leukemia-Chronic Phase Patients Treated With Imatinib: A Local Experience [J].
Al-Amri, Ali M. .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (03) :199-203
[36]   Comprehensive Evaluation of Adherence to Therapy, Its Associations, and Its Implications in Patients With Chronic Myeloid Leukemia Receiving Imatinib [J].
Unnikrishnan, Radhika ;
Veeraiah, Surendran ;
Mani, Samson ;
Rajendranath, Rejiv ;
Rajaraman, Swaminathan ;
Elangovan, Grace Sahaya Vidhubala ;
Radhakrishnan, Venkatraman ;
Ganesan, Trivadi S. ;
Sagar, Tenali G. ;
Ganesan, Prasanth .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (06) :366-+
[37]   Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia [J].
Abbott, Brian L. .
CLINICAL THERAPEUTICS, 2012, 34 (02) :272-281
[38]   Adherence to imatinib therapy in gastrointestinal stromal tumors and chronic myeloid leukemia [J].
Jasem Al-Barrak ;
Winson Y. Cheung .
Supportive Care in Cancer, 2013, 21 :2351-2357
[39]   Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting [J].
Saleh, Mansoor N. ;
Haislip, Sally ;
Sharpe, Joyce ;
Hess, Tamara ;
Gilmore, James ;
Jackson, James ;
Sail, Kavita R. ;
Ericson, Solveig G. ;
Chen, Lei .
CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (04) :529-536
[40]   Imatinib Adherence and Persistence in Patients with Chronic Myeloid Leukemia in Belgium: Evidence from Real-World Data [J].
Michiels, Sandra ;
Tricas-Sauras, Sandra ;
Salaroli, Adriano ;
Bron, Dominique ;
Lewalle, Philippe ;
Vanschoenbeek, Katrijn ;
Poirel, Helene ;
Kirakoya-Samadoulougou, Fati .
PATIENT PREFERENCE AND ADHERENCE, 2024, 18 :1991-2006